Active Ingredient History

NOW
  • Now
Bromocriptine is an ergot derivative with potent dopamine receptor agonist activity, which activates post-synaptic dopamine receptors. Bromocriptine is indicated for the treatment of dysfunctions associated with hyperprolactinemia. Bromocriptine therapy is indicated in the treatment of acromegaly and in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson’s disease. It is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Some commonly reported adverse reactions include nausea, fatigue, dizziness, vomiting and headache. Bromocriptine may interact with dopamine antagonists, butyrophenones and certain other agents.   NCATS

  • SMILES: CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]7CCCN7C1=O)C(C)C
  • InChIKey: OZVBMTJYIDMWIL-AYFBDAFISA-N
  • Mol. Mass: 654.61
  • ALogP: 3.19
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$0.3388 - $6.8790
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

2-bromo-alpha-ergocryptine | 2-bromo-alpha-ergokryptin | 2-bromo-alpha-ergokryptine | 2-bromoergocriptine | 2-bromo-α-ergocryptine | 2-bromo-α-ergokryptin | 2-bromo-α-ergokryptine | (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman | (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione | (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman | bromocriptin | bromocriptina | bromocriptine | bromocriptine mesilate | bromocriptine mesylate | bromocriptinum | bromocryptine | bromoergocriptine | bromoergocryptine | cb-154 | cb-154 mesylate | cycloset | ergolactin | parlodel

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue